FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232153146> ?p ?o ?g. }

• W4232153146 endingPage "27" @default.
• W4232153146 startingPage "26" @default.
• W4232153146 abstract "Sickle cell disease (SCD) results from genetic mutation in the β-globin gene encoding a subunit of the adult form of hemoglobin (HbA), leading to red blood cell (RBC) deformation and disease pathology. It has been demonstrated that reactivation of the fetal ortholog of the hemoglobin beta subunit, HBγ (also referred to as HBG proteins), can prevent or reduce disease-related pathophysiology. In SCD, the presence of HBG protein in hemoglobin tetramers prevents sickle hemoglobin polymerization under deoxygenated conditions and therefore may be of therapeutic benefit in SCD. FTX 6058, a novel orally bioavailable small molecule, is in development for the treatment of sickle cell disease (SCD) by Fulcrum Therapeutics. FTX-6058 was demonstrated to inhibit the novel biological target and elevate the expression of HBγ, resulting in induction of fetal hemoglobin (HbF) tetramer in differentiated human primary CD34+ cells. The in vivo target engagement (TE) and pharmacologic effects of FTX-6058 were characterized in wild-type CD-1 mice and humanized Townes SCD mice, with TE also confirmed in non-human primates. In CD-1 mice, once-daily (QD) FTX-6058 oral administration induced TE in a time- and dose-dependent manner and most markedly in erythroid lineage (Ter119+) cells derived from bone marrow, the putative therapeutic compartment, and increased transcript levels of Hbb-bh1, a murine embryonic hemoglobin surrogate for human HBG gene. Steady state TE in circulating monocytes, following repeated QD FTX-6058 administration, correlated well with that in bone marrow-derived erythroid cells, suggesting peripheral monocytes as a suitable surrogate for assessing erythroid TE activity in Fulcrum's Phase 1 study. In non-human primate cynomolgus monkeys, QD oral dosing of FTX-6058 as early as for 7 days induced robust and comparable TE in bone marrow derived CD34+ erythroid progenitors and circulating monocytes, further supporting the use of monocytes to assess TE in bone marrow. Mouse data also provided evidence of the reversibility of TE effects once dosing is stopped. In repeat-dose studies in the humanized Townes SCD mouse model, FTX-6058 was superior to standard of care hydroxyurea as measured by human HBG1 transgene induction and increased %F-cells and HBG1 protein levels. Furthermore, the induction of %F cells was sustainable for several days after dosing cessation. These in vivo studies have demonstrated that FTX-6058 engages its novel biological target in multiple preclinical models and induces HbF expression at plasma concentrations likely to b e readily achievable in clinic, and peripheral monocytes is a suitable surrogate for assessing TE in bone marrow erythroid cells, which could be beneficial to patients with SCD. Disclosures Xie: Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Roth:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Efremov:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Silver:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Ronco:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Thompson:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Stickland:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Moxham:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company. Wallace:Fulcrum Therepeutics: Current Employment, Current equity holder in publicly-traded company." @default.
• W4232153146 created "2022-05-12" @default.
• W4232153146 creator A5008435208 @default.
• W4232153146 creator A5042569887 @default.
• W4232153146 creator A5046374697 @default.
• W4232153146 creator A5049853983 @default.
• W4232153146 creator A5056108229 @default.
• W4232153146 creator A5058828506 @default.
• W4232153146 creator A5065362371 @default.
• W4232153146 creator A5068194637 @default.
• W4232153146 creator A5071157451 @default.
• W4232153146 date "2020-11-05" @default.
• W4232153146 modified "2023-09-26" @default.
• W4232153146 title "<i>In Vivo</i> Characterization of Ftx-6058, a Novel Small Molecular Fetal Hemoglobin Inducer for Sickle Cell Disease" @default.
• W4232153146 doi "https://doi.org/10.1182/blood-2020-139566" @default.
• W4232153146 hasPublicationYear "2020" @default.
• W4232153146 type Work @default.
• W4232153146 citedByCount "2" @default.
• W4232153146 countsByYear W42321531462021 @default.
• W4232153146 countsByYear W42321531462022 @default.
• W4232153146 crossrefType "journal-article" @default.
• W4232153146 hasAuthorship W4232153146A5008435208 @default.
• W4232153146 hasAuthorship W4232153146A5042569887 @default.
• W4232153146 hasAuthorship W4232153146A5046374697 @default.
• W4232153146 hasAuthorship W4232153146A5049853983 @default.
• W4232153146 hasAuthorship W4232153146A5056108229 @default.
• W4232153146 hasAuthorship W4232153146A5058828506 @default.
• W4232153146 hasAuthorship W4232153146A5065362371 @default.
• W4232153146 hasAuthorship W4232153146A5068194637 @default.
• W4232153146 hasAuthorship W4232153146A5071157451 @default.
• W4232153146 hasConcept C125996951 @default.
• W4232153146 hasConcept C153911025 @default.
• W4232153146 hasConcept C172680121 @default.
• W4232153146 hasConcept C203014093 @default.
• W4232153146 hasConcept C207001950 @default.
• W4232153146 hasConcept C2776317666 @default.
• W4232153146 hasConcept C2778917026 @default.
• W4232153146 hasConcept C2779234561 @default.
• W4232153146 hasConcept C2780007613 @default.
• W4232153146 hasConcept C54355233 @default.
• W4232153146 hasConcept C55493867 @default.
• W4232153146 hasConcept C86803240 @default.
• W4232153146 hasConceptScore W4232153146C125996951 @default.
• W4232153146 hasConceptScore W4232153146C153911025 @default.
• W4232153146 hasConceptScore W4232153146C172680121 @default.
• W4232153146 hasConceptScore W4232153146C203014093 @default.
• W4232153146 hasConceptScore W4232153146C207001950 @default.
• W4232153146 hasConceptScore W4232153146C2776317666 @default.
• W4232153146 hasConceptScore W4232153146C2778917026 @default.
• W4232153146 hasConceptScore W4232153146C2779234561 @default.
• W4232153146 hasConceptScore W4232153146C2780007613 @default.
• W4232153146 hasConceptScore W4232153146C54355233 @default.
• W4232153146 hasConceptScore W4232153146C55493867 @default.
• W4232153146 hasConceptScore W4232153146C86803240 @default.
• W4232153146 hasIssue "Supplement 1" @default.
• W4232153146 hasLocation W42321531461 @default.
• W4232153146 hasOpenAccess W4232153146 @default.
• W4232153146 hasPrimaryLocation W42321531461 @default.
• W4232153146 hasRelatedWork W1558480946 @default.
• W4232153146 hasRelatedWork W160982055 @default.
• W4232153146 hasRelatedWork W1724074182 @default.
• W4232153146 hasRelatedWork W2024654990 @default.
• W4232153146 hasRelatedWork W2033349520 @default.
• W4232153146 hasRelatedWork W2074646812 @default.
• W4232153146 hasRelatedWork W261888440 @default.
• W4232153146 hasRelatedWork W384279908 @default.
• W4232153146 hasRelatedWork W4236798873 @default.
• W4232153146 hasRelatedWork W2492130407 @default.
• W4232153146 hasVolume "136" @default.
• W4232153146 isParatext "false" @default.
• W4232153146 isRetracted "false" @default.
• W4232153146 workType "article" @default.